tiprankstipranks
Trending News
More News >

Avidity Biosciences price target raised to $59 from $57 at Barclays

Barclays raised the firm’s price target on Avidity Biosciences (RNA) to $59 from $57 and keeps an Overweight rating on the shares. The company’s Facioscapulohumeral muscular dystrophy update “checked the key boxes,” but stock was under pressure due to concerns of definitive accelerated approval, the analyst tells investors in a research note. The firm says that while the FDA required evidence to “reasonably predict clinical benefit,” it believes current data largely support cDUX as a good biomarker.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1